Neurolens announced it raised $67.6 Million in an initial filing from an offering of $67.6 Million

Company

Location

About

As many as 80% of people experience reduced visual acuity and symptoms due to eye misalignment. Even small misalignments can cause poor vision and painful symptoms, and even small prism corrections can provide dramatic results. Historically, however, measuring small amounts of prism has been all but impossible. But now is the time to transform your practice with Neurolens. Our newest innovation, N3, is an immersive, engaging patient experience that educates while measuring. N3 is a fast and accurate way for any eyecare provider to measure eye misalignment down to a fraction of a prism diopter. The diagnostic information from N3 is used to prescribe Neurolenses with patented contoured prism technology, which bring the eyes into alignment, relieving symptoms like headaches and eye strain for 93% of wearers. Learn more about becoming a Neurolens provider at neurolens.com and join the new standard of care providing dramatic patient outcomes and practice success.